Oncology

Back to articles

New lenalidomide data show improved survival benefits, continuing safety concerns

KEY POINT

Lenalidomode (Revlimid—Celgene) improved progression-free survival for multiple myeloma when administered as initial therapy in patients who were ineligible for stem-cell transplantation, and as maintenance therapy in patients who received stem-cell transplantation, according to three recent studies. Lenalidomide was associated with a higher incidence of second primary cancers in all three trials.

SOURCES

Palumbo et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–69. 

McCarthy PL et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81. 

Attal M. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91. 

Badros AZ. Lenalidomide in myeloma: a high-maintenance friend [editorial]. N Engl J Med. 2012;366:1836–8.